First-of-a-kind once daily pill given regulatory green light for patients with rare type of skin cancer, UK

Patients with advanced basal cell carcinoma who are not suitable for surgery or radiotherapy, could benefit from Erivedge (vismodegib) which is available following conditional EMA authorisation for use in the UK and listing on the national Cancer Drugs Fund (CDF).*[1],[2] Basal cell carcinoma (BCC) is the most common form of skin cancer in the UK[3],[4] and is often found on the head and neck...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news